Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

The effects of organic nitrates on osteoporosis: a systematic review.

Jamal SA, Reid LS, Hamilton CJ.

Osteoporos Int. 2013 Mar;24(3):763-70. doi: 10.1007/s00198-012-2262-9. Epub 2013 Jan 11. Review.

PMID:
23306823
2.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Jul 19;(3):CD005326. Review. Update in: Cochrane Database Syst Rev. 2006;(4):CD005326.

PMID:
16856092
3.
4.

Nitric oxide donors for the treatment of osteoporosis.

Jamal SA, Hamilton CJ.

Curr Osteoporos Rep. 2012 Mar;10(1):86-92. doi: 10.1007/s11914-011-0087-7. Review.

PMID:
22210559
5.

Strontium ranelate for preventing and treating postmenopausal osteoporosis.

O'Donnell S, Cranney A, Wells GA, Adachi JD, Reginster JY.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005326. Review.

PMID:
17054253
6.

Bisphosphonate therapy for children and adolescents with secondary osteoporosis.

Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005324. Review.

PMID:
17943849
7.

Bisphosphonates for osteoporosis in primary biliary cirrhosis.

Rudic JS, Giljaca V, Krstic MN, Bjelakovic G, Gluud C.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009144. doi: 10.1002/14651858.CD009144.pub2. Review.

PMID:
22161446
8.

Interventions for the treatment of decreased bone mineral density associated with HIV infection.

Lin D, Rieder MJ.

Cochrane Database Syst Rev. 2007 Apr 18;(2):CD005645. Review.

PMID:
17443607
9.

Bisphosphonates for osteoporosis in people with cystic fibrosis.

Conwell LS, Chang AB.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD002010. doi: 10.1002/14651858.CD002010.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;4:CD002010.

PMID:
19821288
10.

Efficacy of strontium ranelate on bone mineral density in men with osteoporosis.

Ringe JD, Dorst A, Farahmand P.

Arzneimittelforschung. 2010;60(5):267-72.

PMID:
20533764
11.

Vitamin K to prevent fractures in older women: systematic review and economic evaluation.

Stevenson M, Lloyd-Jones M, Papaioannou D.

Health Technol Assess. 2009 Sep;13(45):iii-xi, 1-134. doi: 10.3310/hta13450. Review.

12.

Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.

Gallagher JC, Rosen CJ, Chen P, Misurski DA, Marcus R.

Bone. 2006 Dec;39(6):1268-75. Epub 2006 Aug 1.

PMID:
16884968
13.

Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis.

Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C.

Osteoporos Int. 2013 Jan;24(1):209-17. doi: 10.1007/s00198-012-2068-9. Epub 2012 Jul 26.

14.

Meta-analysis of walking for preservation of bone mineral density in postmenopausal women.

Martyn-St James M, Carroll S.

Bone. 2008 Sep;43(3):521-31. doi: 10.1016/j.bone.2008.05.012. Epub 2008 May 26.

PMID:
18602880
15.

Bisphosphonates for osteoporosis in people with cystic fibrosis.

Brenckmann C, Papaioannou A.

Cochrane Database Syst Rev. 2001;(4):CD002010. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD002010.

PMID:
11687132
16.

Comparison of clinical efficacy and safety between denosumab and alendronate in postmenopausal women with osteoporosis: a meta-analysis.

Lin T, Wang C, Cai XZ, Zhao X, Shi MM, Ying ZM, Yuan FZ, Guo C, Yan SG.

Int J Clin Pract. 2012 Apr;66(4):399-408. doi: 10.1111/j.1742-1241.2011.02806.x. Epub 2012 Feb 7. Review.

PMID:
22313934
17.

Antifracture efficacy of currently available therapies for postmenopausal osteoporosis.

Reginster JY.

Drugs. 2011 Jan 1;71(1):65-78. doi: 10.2165/11587570-000000000-00000. Review.

PMID:
21175240
18.

Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.

Richy F, Schacht E, Bruyere O, Ethgen O, Gourlay M, Reginster JY.

Calcif Tissue Int. 2005 Mar;76(3):176-86. Epub 2005 Feb 7.

PMID:
15692726
19.

Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.

Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P.

Osteoporos Int. 2007 Jan;18(1):45-57. Epub 2006 Sep 2. Review.

PMID:
16951908
20.

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.

Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD.

J Bone Miner Res. 2009 Apr;24(4):719-25. doi: 10.1359/jbmr.081214.

Items per page

Supplemental Content

Write to the Help Desk